Diaceutics Blog | Diaceutics

Real Time Oncology Review (RTOR) – implications for launch and commercialization

23rd August 2018
The FDA intends to make the development and review of cancer drugs more efficient under the Real Time Oncology Review (RTOR) pilot program. Under this supplemental applications pilot, launched last year, evaluation of clinical data begins as soon as clinical data becomes available and results are

Innovation in Liquid Biopsy

22nd August 2018
The term “liquid biopsy” is defined by the College of American Pathologists (CAP) as assays that analyze proteins, DNA, or cancer cells that circulate in the blood. There is growing interest in the less invasive, less complicated liquid biopsy as an alternative option to traditional biopsies in

Trends in FLT3 testing

7th August 2018
The FMS-like tyrosine kinase 3 gene (FLT3) marker is present in 25-30% of all AML patients and indicates a poorer prognosis.  The testing landscape is evolving and FLT3 diagnostic testing is now used in efficacy-based patient stratification, safety-based patient stratification and ongoing

Spark and laboratory data

25th July 2018
At Diaceutics we are using a number of tools to leverage our data and to generate actionable insights.  We mine data to forecast market trends and to understand the changing biomarker landscape.  We are able to understand the use of new biomarker targets over time, review the dissemination of new

Precision Medicine (PM) and Artificial Intelligence (AI) algorithms – risk of bias in treatment

26th June 2018
Precision medicine is more impactful when we build a story through use of a complete and meaningful dataset. Many publications discuss the idea that precision medicine relies on smart technology and this is true. At Diaceutics we believe that smart technology needs to be paired with the right

CMS decision on NGS coverage is a big step forward for patients and laboratories

20th April 2018
By Jeff Schreier, Senior Director, Marketing and Robert Feeney, Marketing Director, Global Lab Relations, Diaceutics.  A hurdle has just been cleared for patients and the laboratories who serve them. On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National

Diaceutics, Intel and Lenovo advance patient care using AI and workstations powered by Intel® Xeon® Scalable processors

5th March 2018
Collaboration will help to organize and categorize patient testing data using artificial intelligence It is a revolutionary method which could help to identify new patient subsets The aim is to further improve the diagnosis and treatment of patients Since it was established, Diaceutics has focused

It’s a boy! Now where’s that genetic testing kit? 

28th February 2018
In a big step forward for early diagnostic use, US company Sema4 has begun offering a newborn genetic screening kit that analyses 166 genes for 193 disorders and 38 common pediatric diseases. Sema4 is a “health information company founded on the idea that more information, deeper

Could Crohn’s disease treatment become more precise?

19th February 2018
Crohn’s disease is an inflammatory condition that affects the gastrointestinal tract and can cause symptoms including abdominal pain, diarrhoea, bleeding, joint pain, mouth sores, fatigue and weight loss. The cause is unknown but bacteria and the immune system are implicated and there is

A diagnostic for Alzheimer’s is as important as finding a therapy

9th January 2018
Alzheimer’s is a disease, very much like cancer, that affects so many of us, if not directly then through the experience of a family member or friend. There are currently 5 million people in the US living with Alzheimer’s and given that the western population experiences increasingly longer

Drive-through diagnostic testing?

13th December 2017
A story in the UK press on 21 November 2017, Cancer tests in supermarket car parks in bid to boost detection rates, elicited the comment from Diaceutics of “Now that’s progress!” Our vision is that better testing leads to better patient outcomes and earlier diagnosis in the patient journey is

Sea breezes and sunshine for Diaceutics cyclists

11th December 2017
If you’re going to take part in a charity cycle race for cancer, then where better than California? This was the sunny setting for Ewelina Golebiewska and John McNamara from Diaceutics as they joined Team Pfizer in November 2017 on the two-day Padres Pedal the Cause event. “The scenery was
Load more